补体与动脉粥样硬化

[1] Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty （COMMA） Trial[J] . Christopher B. Granger,Kenneth W. Mahaffey,W. Douglas Weaver,Pierre Theroux,Judith S. Hochman,Thomas G. Filloon,Scott Rollins,Thomas G. Todaro,Jose C. Nicolau,Witold Ruzyllo,Paul W. Armstrong.Circulation: Journal of the American Heart Association . 2003 (10)

[2] Diabetes[P]. 英国专利:GB201117172D0,2011-11-16

[3] Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Koistinen HA,Vidal H,Karonen SL, et al. Arteriosclerosis and Thrombosis . 2001

[1] Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty （COMMA） Trial[J] . Christopher B. Granger,Kenneth W. Mahaffey,W. Douglas Weaver,Pierre Theroux,Judith S. Hochman,Thomas G. Filloon,Scott Rollins,Thomas G. Todaro,Jose C. Nicolau,Witold Ruzyllo,Paul W. Armstrong.Circulation: Journal of the American Heart Association . 2003 (10)

[2] Diabetes[P]. 英国专利:GB201117172D0,2011-11-16

[3] Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Koistinen HA,Vidal H,Karonen SL, et al. Arteriosclerosis and Thrombosis . 2001